11 Comments
 

To add to this, Ascend Partners (investment team, MD cofounder) and Consonance Capital Partners (very legit operating team, familiar with a clinician on their team). Ditto on Regal.

If you're in the NYC area, PM me and I can give you some MDs I'm aware of in the PE/VC space. May not be a bad idea to cold message them via LinkedIn.

Disagree on biotech VC comment below. Very volatile but agree with the top answer here. Have seen operating / value creation roles for MD eventually lead to juicy equity options and in some cases, investment roles at smaller PE funds that do a mix of growth and buyout within the HC service space.

 

PE not so likely, however your best bet to breaking into high finance is VC biotech firms where they focus on pre-seed, seed and series A investments. Where your science and healthcare background has the most leverage vs later stage investments or pure PE firms where the knowledge of finance and required background is much more finance focused. 

My two cents is that this funnel is your best shot, as if you look at a lot of VC biotech firms you'll see their background (which is more often than not a requirement) is to have a phd or MD in a valued added field. Take a look at Arch Ventures in Chicago, I would say this is one of the crim de la crims of biotech VC but there's an example of what I'm talking about. Still get carry, still in high finance, still writing checks, making big checks, still business, etc etc. But this way you'll be able to leverage your current network, your background and most likely also passion and interest for healthcare. PM (private message) me if you want. 

Edit: and yes per my comment above about being a requirement for biotech VC, lots of MDs and phds go into biotech VC. Also I went to a very medicine focused school so I can attest to this. 

 

Ipsum voluptatem mollitia quod fuga et aut soluta. Earum amet et et facere est. Eos earum et fugit quo et qui. Nihil necessitatibus esse enim perferendis fugiat voluptatem.

Tenetur commodi saepe at modi quidem eum tenetur. Sunt sunt suscipit consequatur recusandae. Ratione sed beatae excepturi ipsam nihil architecto. Voluptas molestiae est temporibus. Recusandae earum ut atque omnis minus quia ea.

Career Advancement Opportunities

July 2026 Private Equity

  • The Riverside Company 99.6%
  • Blackstone Group 99.3%
  • KKR (Kohlberg Kravis Roberts) 98.9%
  • Warburg Pincus 98.5%
  • Vista Equity Partners 98.1%

Overall Employee Satisfaction

July 2026 Private Equity

  • Blackstone Group 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.3%
  • The Riverside Company 98.9%
  • Ardian 98.5%
  • Warburg Pincus 98.1%

Professional Growth Opportunities

July 2026 Private Equity

  • Bain Capital 99.6%
  • The Riverside Company 99.3%
  • Blackstone Group 98.9%
  • Starwood Capital Group 98.5%
  • KKR (Kohlberg Kravis Roberts) 98.1%

Total Avg Compensation

July 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (99) $363
  • 3rd+ Year Associate (104) $281
  • 2nd Year Associate (235) $272
  • 1st Year Associate (411) $229
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (97) $134
  • 1st Year Analyst (272) $124
  • Intern/Summer Associate (38) $81
  • Intern/Summer Analyst (355) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
DrApeman's picture
DrApeman
98.9
6
dosk17's picture
dosk17
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
CompBanker's picture
CompBanker
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”